29.2 C
Vientiane
Thursday, August 14, 2025
spot_img
Home Blog Page 1250

Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

  • Serplulimab is the world’s first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC
  • Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) for the treatment of ES-SCLC
  • Serplulimab has now been approved in China, Europe, and several Southeast Asian countries, benefiting over 90,000 patients

SHANGHAI, Feb. 5, 2025 /PRNewswire/ — Shanghai Henlius Biotech, Inc. (2696.HK) announced that its anti-PD-1 mAb, HANSIZHUANG (serplulimab, marketed as Hetronifly® in Europe), has been officially approved by the European Commission (EC) for use in combination with carboplatin and etoposide as a first-line treatment of adult patients with ES-SCLC. This approval establishes serplulimab as the first and only anti-PD-1 mAb approved in the EU for the treatment of ES-SCLC.

Serplulimab is the world’s first anti-PD-1 mAb approved for first-line treatment of ES-SCLC. Underpinned by clinical needs, Henlius has carried out a differentiated and multi-dimensional layout of serplulimab in the fields of lung cancer and gastrointestinal cancer. To date, more than 4,800 subjects have been enrolled worldwide for clinical trials of serplulimab. In 2023, Henlius entered into a collaboration with Intas Pharmaceuticals, granting Intas exclusive rights to develop and commercialise serplulimab in over 50 countries across Europe and India. This latest approval covers all 27 EU member states as well as the European Economic Area countries, including Norway, Iceland, and Liechtenstein. Commercialisation in Europe will be led by Intas’ subsidiary, Accord Healthcare Ltd (“Accord”).

Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, stated: “The approval of serplulimab in the EU represents another significant step forward in our mission to benefit patients worldwide. This milestone not only underscores our leadership in innovative drug development and global strategy, but also brings new hope to ES-SCLC patients in Europe and beyond. Moving forward, we will continue to collaborate with our partners to enhance the accessibility of advanced therapies and work together to make a meaningful difference in patients’ lives.”

Breakthrough Innovation to Address Unmet Clinical Needs

Lung cancer is the most common cancer worldwide in terms of incidence and mortality. According to GLOBOCAN 2022, there were over 2.48 million new cases of lung cancer globally in 2022, accounting for 12.4% of all new cancer cases.[1] Small cell lung cancer (SCLC), which accounts for 15% to 20% of all lung cancers, is characterised by high malignancy, early metastasis, rapid progression, and poor prognosis. Among SCLC patients, approximately 30% to 40% are diagnosed at a limited stage, while the remaining cases are in extensive stage. In the EU, the prevalence of SCLC ranges from 1 to 5 per 10,000 people.[2] In December 2022, serplulimab received orphan drug designation from the EC for the treatment of SCLC. The orphan-drug designation granted by the EC is beneficial for serplulimab to enjoy certain policy supports in the R&D, registration and commercialisation in the treatment of SCLC in the EU. In September 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending Hetronifly® for approval in the EU.

The approval of serplulimab by the EC is primarily based on data from the ASTRUM-005 study, a randomized, double-blind, placebo-controlled international multi-centre Phase 3 study evaluating the efficacy and safety event profile of serplulimab in combination with chemotherapy versus placebo with chemotherapy as a first-line treatment for ES-SCLC. The study has set up a total of 128 sites across countries including China, Poland, Turkey, and Georgia, enrolling 585 subjects, of whom around 31.5% were Caucasians. Results from ASTRUM-005 were first presented orally at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and later published in the Journal of the American Medical Association (JAMA), making it the first SCLC immunotherapy study to publish on JAMA. Based on ASTRUM-005, serplulimab has been approved in China, Southeast Asian countries, and the EU for the first-line treatment of ES-SCLC, establishing it as the world’s first anti-PD-1 mAb approved for the indication. Additionally, Henlius is conducting a head-to-head bridging trial in the U.S. comparing serplulimab with atezolizumab, the current standard of care, to further support its U.S. regulatory submission.

Global Expansion to Benefit More Patients

Henlius’ commitment to stringent quality standards has been instrumental in achieving EC approval for serplulimab. In 2023, Henlius’ manufacturing facilities and production lines of serplulimab successfully passed EU GMP inspections, ensuring a stable and high-quality supply of serplulimab for the European market. Henlius operates three facilities in Shanghai—Xuhui Facility, Songjiang First Plant, and Songjiang Second Plant—with a total commercial capacity of 48,000 litres, ensuring consistent global supply to regions including China, Europe, Latin America, the Middle East, North America, and Southeast Asia. The company has implemented a comprehensive quality management system in line with international standards, covering the entire product continuum ranging from R&D to material management, product manufacturing, quality control, product supply management and post-marketing surveillance. The company’s facilities and quality systems have been audited and certified by regulatory authorities including the National Medical Products Agency (NMPA), European Medicines Agency (EMA), United States Food and Drug Administration (FDA), and international business partners.

Henlius has established a robust global presence through partnerships with Accord, KGbio, and Fosun Pharma, extending its reach to over 70 countries and regions, including the U.S., Europe, Southeast Asia, and emerging markets. Looking ahead, Henlius will continue to work closely with its partners to expand the availability of serplulimab to more countries and regions, providing broader treatment options to patients worldwide.

Reference

[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834

[2] Dingemans AC, Früh M, Ardizzoni A, et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Ann Oncol. 2021;32(7):839-853. doi:10.1016/j.annonc.2021.03.207

About Serplulimab

HANSIZHUANG (recombinant humanized anti-PD-1 monoclonal antibody injection, generic name: serplulimab injection) is the first anti-PD-1 mAb for the first-line treatment of SCLC and has been approved in China, the EU and several SEA countries. Focusing on lung and gastrointestinal cancer, the synergy of HANSIZHUANG with in-house products of the company and innovative therapies are being actively promoted. Up to date, HANSIZHUANG has been approved by the National Medicinal Products Administration (NMPA) for the treatment of squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ES-SCLC), esophageal squamous cell carcinoma (ESCC) and non-squamous non-small cell lung cancer (nsNSCLC). Serplulimab was granted orphan drug designations by the FDA and the EC for the treatment of SCLC, and its bridging head-to-head trial in the United States to compare HANSIZHUANG to standard of care atezolizumab (anti-PD-L1 mAb) for the first-line treatment of ES-SCLC is well under way.

The results of 4 pivotal trials of HANSIZHUANG were published in the Journal of the American Medical Association (JAMA), Nature MedicineCancer Cell and British Journal of Cancer, respectively. Furthermore, HANSIZHUANG was respectively recommended by the CSCO Guidelines for Small Cell Lung Cancer, the CSCO Guidelines for Non-Small Cell Lung Cancer, the CSCO Guidelines for Esophageal Cancer, the CSCO Clinical Practice Guidelines on Immune Checkpoint Inhibitor, the China Guidelines for Radiotherapy of Esophageal Cancer, and other definitive guides, providing valuable references for clinical diagnosis and treatment of tumours.

About Henlius

Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. Up to date, 6 products have been launched in China, 4 have been approved for marketing in overseas markets, and 4 marketing applications have been accepted for review in China, the U.S. and the EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation centre and Shanghai-based commercial manufacturing facilities certificated by China, the EU and U.S. GMP.

Henlius has pro-actively built a diversified and high-quality product pipeline covering over 50 molecules and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as the backbone. To date, the company’s launched products include HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe), a China-developed mAb biosimilar approved in China, Europe and U.S., HANDAYUAN (adalimumab), HANBEITAI (bevacizumab), HANSIZHUANG, the world’s first anti-PD-1 mAb for the first-line treatment of SCLC, and HANNAIJIA (neratinib). What’s more, Henlius has conducted over 30 clinical studies for 16 products, expanding its presence in major markets as well as emerging markets.

NYSE CONTENT ADVISORY: PRE-MARKET UPDATE FOR FEBRUARY 5th

NEW YORK, Feb. 5, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) is proud to offer a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

 

Feb_5_2025_Market_Update

Kristen Scholer delivers the pre-market update on February 5th

  • Amid disappointing earnings results, stocks lower in extended trade
  • China announces 15% levy on U.S. goods
  • Alphabet earnings miss estimates in latest quarter

Watch NYSE TV Live every weekday 9:00-10:00am ET 

 

TUMI UNVEILS MULTI-YEAR PARTNERSHIP WITH MASTER & DYNAMIC

Introducing 19 Degree-inspired earphones, blending iconic TUMI design with premium sound technology

NEW YORK, Jan. 29, 2025 /PRNewswire/ — Today, international travel and lifestyle brand TUMI announces an exciting collaboration with premium audio brand Master & Dynamic. The first launch of this multi-year partnership unveils a pair of state-of-the-art noise-canceling earphones, featuring TUMI’s iconic 19 Degree design details. A seamless blend of engineering precision and artistic expression, this collaboration effortlessly combines the best of both brands.

MW09 Active Noise Canceling Earphones in Black
MW09 Active Noise Canceling Earphones in Black

“Our customers expect the very best from TUMI, which is why we’ve partnered with Master & Dynamic—a brand renowned for crafting premium, high-quality audio products,” said TUMI Creative Director Victor Sanz. “This collaboration brings together two seemingly distinct worlds that, in reality, complement each other perfectly. When the iconic contours of 19 Degree combine with the superior engineering of Master & Dynamic, the result is not just an elevated piece of tech—it’s a work of art.”

The launch introduces the MW09 Active Noise-Canceling True Wireless Earphones, engineered for premium performance and durability, featuring an IP54 water resistance rating and an advanced 6-microphone talk system with wind noise reduction. Available in two sleek core colorways—black and silver—the earphones are thoughtfully designed to complement TUMI’s iconic 19 Degree Aluminum collection. This release marks just the beginning, with TUMI poised to reveal additional collections from this exciting collaboration as the year unfolds

“Travel has always been a part of Master & Dynamic’s DNA and sound plays an essential role in every journey,” said Jonathan Levine, CEO and founder of Master & Dynamic. “Partnering with TUMI, a brand known for combining beauty, functionality and durability – felt like a natural fit. Together we’ve created a collection of high-performance sound tools designed for global travelers.”

The MW09 Active Noise Canceling Earphones will retail for $450 USD and are available for purchase worldwide at TUMI.com, select TUMI Retail Stores and at masterdynamic.com.

About TUMI 
Since 1975, TUMI has been creating world-class business, travel, and performance luxury essentials, designed to upgrade, uncomplicate and beautify all aspects of life on the move. Blending flawless functionality with a spirit of ingenuity, we’re committed to empowering journeys as a lifelong partner to movers and makers in pursuit of their passions. For more about TUMI, visit TUMI.com

TUMI and TUMI logo are registered trademarks of Tumi, Inc. © 2025 Tumi, Inc.

TUMI Media Contacts
TUMI 
Jerad Hulse
Jerad.hulse@tumi.com

About Master & Dynamic
Since its launch in 2014, New York City-based luxury audio brand Master & Dynamic has released a variety of award-winning audio products ranging from wired and wireless headphones to a wireless speaker; recently the MW75 Active Noise-Cancelling Headphones were recognized for world class design as the winner of The Red Dot Award: Product Design 2023. With an unrelenting attention to craft and detail, Master & Dynamic has a deep passion for building beautifully crafted and technically sophisticated sound tools to help focus, inspire and transport your mind.

Designed to be modern yet timeless, Master & Dynamic products utilize only the finest materials and are engineered to last, creating the perfect balance of aesthetics, strength, comfort and exceptional sound. With collaborations from world-renowned luxury brands like Louis Vuitton and Mercedes-Benz, Master & Dynamic believes mastery is a never-ending exploration requiring a dynamic approach. View the entire collection at www.masterdynamic.com and join the conversation at @masterdynamic.

Master & Dynamic Media Contacts
Sarah Dominguez
Sarah.Dominguez@masterdynamic.com

MW09 Active Noise Canceling Earphones in Silver
MW09 Active Noise Canceling Earphones in Silver

 

 

I Peace establishes and offers low immunoreaction risk GMP iPS Cells

Three lines of GMP iPS Cells derived from type O female blood are now offered as off-the-shelf product

PALO ALTO, Calif., Feb. 5, 2025 /PRNewswire/ — Leading GMP cell CDMO I Peace, Inc. (https://ipeace.com/en/), specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the company has established low immunoreaction risk GMP iPSCs derived from type O female blood and started offering as an off-the-shelf product.

It is well known that HLA homozygous iPSCs are often selected to reduce adverse immune response in patients, however, there has recently been an increased demand for type O female blood-derived iPSCs. Type O female blood-derived iPSCs have multiple merits including the low immunoreaction risk from ABO blood type and Y chromosome-derived proteins.

With the offering of these off-the-shelf, low immunoreaction risk iPSCs, I Peace’s iPSC offerings have been enriched to serve a wider variety of cell therapy developers and pharmaceutical companies.

Advantages of type O blood-derived iPSCs

Because of the absence of A or B antigens, type O blood donors are considered “universal donors” for blood transfusions. Likewise, iPS cells derived from type B lymphocytes demonstrate greater universal compatibility, simplifying the logistics of matching donor cells to recipients.

Advantages of female donor-derived iPSCs

Male donors contribute a Y chromosome, which is smaller, contains fewer genes, and is prone to specific genetic instabilities during extended culture or reprogramming processes. This could impact the quality or safety of iPSC-derived therapies. Female donors avoid this risk, potentially leading to greater genetic stability in the iPSC line.

Proteins encoded by the Y chromosome may also act as antigens and trigger immune responses in female recipients. Female-derived cells lack these antigens, making them more universally applicable. Furthermore, female-derived iPSCs may be preferred for studies or therapies related to female-specific diseases or conditions, as they inherently reflect female physiology.

I Peace will continue to provide iPSCs and cell-related CDMO services to more companies and institutions to bring iPSC-derived therapies closer to everyone.

I Peace, inc.

I Peace, inc. provides GMP iPS cells globally and is an entrusted manufacturing service provider of various medical grade cells. The company was founded in 2015 by Koji Tanabe, a graduate of Professor Shinya Yamanaka’s laboratory at Kyoto University, and the second author of the paper that reported the successful establishment of the world’s first human iPS cell line. Tanabe has been involved in iPS cell research since the early days of its development and is working daily on innovative technical developments to make iPS cells accessible to everyone through I Peace, inc.

Our unique technology enables us to produce multiple donor-derived iPS cells in parallel without contamination concerns and to provide scalable iPS cell manufacturing at a reasonable price. We are also promoting the production of iPS cells for individuals so that everyone in the world can prepare for the future by preserving their own iPS cells.

We support drug discovery and cell medicine development by providing iPS cells and other cell products that meet PMDA and FDA standards to pharmaceutical and cell medicine development companies so that cell medicine can become available to patients as soon as possible. Our ultimate goal is to enhance the prevalence of regenerative medicine by establishing iPS cell banking services for individuals and making iPS cells accessible to other development companies working with this incredible technology.

I Peace, Inc.
Founder & CEO: Koji Tanabe
Established: 2015
Headquarters: Palo Alto, California, U.S.A.
Subsidiary in Japan: I Peace, Ltd., Kyoto
iPS cell manufacturing base: Peace Engine Kyoto, Kyoto
Website: https://ipeace.com/en/ 

TRILLER PUTS CREATORS FIRST AS IT UNLEASHES THE FUTURE OF TECH, MUSIC & CULTURE WITH THE LATEST VERSION OF ITS APP

Powered by next-generation technology and with data privacy front and center, Triller is redefining the creator economy with new ways for brands and creators to own their content, connect with their fans, and manage their audiences 

LOS ANGELES, Feb. 5, 2025 /PRNewswire/ — Triller is at the forefront of the creator economy revolution, launching a new and improved tech platform designed to empower creators to take full control of their brand, engage with fans, and transform passion into profit. With a suite of next-gen tools and innovative features, Triller is rewriting the playbook on how creators distribute content, foster authentic relationships with their audience, and monetize their influence.

“Triller is not just a platform; it’s a movement that elevates creators to new heights. We’re giving them everything they need to own their content and their audience, from start to finish,” said Sean Kim, Triller’s newly appointed CEO and Former Head of Products at TikTok.

As top influencers and celebrities flock to Triller, they’re bringing their massive fanbases along with them, attracted by a platform that puts creators first. Triller’s dynamic ecosystem of cutting-edge tools allows creators to produce, distribute, and track content effortlessly while maintaining full ownership and control. Whether crafting viral videos or building lasting connections with superfans, Triller unlocks unprecedented opportunities for creators.

“What many people don’t know is that Triller is more than just a short-form video app—it’s an entire creator ecosystem,” said Manoj Malhotra, SVP of Technology Operations at Triller. “Our AI-powered features and audience engagement tools are specifically designed to supercharge creators’ reach and engagement, driving results in a way no other platform can.”

Triller’s technology platform gives creators unparalleled control over their work and audience; Creators can control how and when they engage with their fans, ensuring authentic connections and the ability to monetize without interference.

“Triller is redefining the creator economy by offering a platform that combines cutting-edge technology, privacy-first policies, and a commitment to supporting creators’ independence,” said Malhotra. “It’s a more accountable, data-friendly alternative to TikTok, ensuring that creators have the freedom to thrive without compromising their values.”

With the latest updates to the Triller app, shadowbans, and unpredictable algorithm changes are a thing of the past.  And with features like AI-powered messaging and streamlined campaign management, creators have the tools to connect and engage with their audiences and maximize monetization opportunities.

Data Privacy & User Safety

Amid uncertainty around data privacy, Triller stands out by prioritizing user security. As a U.S.-owned company, Triller ensures users’ information is kept safe and private. On the Triller app, creators and their fans can engage confidently, knowing their data and conversations are secure.

Music at the Heart of the Triller Experience

Music is at the core of the Triller experience, setting the platform apart from its competitors. Triller amplifies music’s role in connecting creators with their fans, from exclusive previews by A-list artists to emerging talent finding their voice. The platform has been pivotal in launching the careers of artists such as Lil Nas X, GloRilla, Coi Leray and Popphunna. Whether it’s building communities or creating viral music moments, Triller turns music into the ultimate tool for connection.

“Triller has become a launchpad for artists who are shaping today’s music culture,” said Melissa Philipian, Head of Music Partnerships at Triller. “From breakout stars to global icons, artists are leveraging Triller to connect with fans, drive engagement, and create viral moments that propel their careers forward.”

Triller’s innovative approach has attracted a star-studded roster of celebrity investors and industry leaders such as The Weeknd, Lil Wayne, French Montana, Dababy, who believe in its creator-first mission.

To discover how Triller is changing the game for creators, visit trillerinc.com and download the app from the Google Play or Apple App Store today!

About Triller Group Inc.  

Nasdaq: ILLR. Triller Group is a US-based company that operates two main businesses: the newly merged US-based social media operations (Triller Corp.), and the legacy operations of the Company in Hong Kong (“AGBA”).

Triller Corp. is a next-generation, AI-powered, social media and live-streaming event platform for creators. Pairing music culture with sports, fashion, entertainment, and influencers through a 360-degree view of content and technology, Triller Corp. uses proprietary AI technology to push and track content virally to affiliated and non-affiliated sites and networks, enabling them to reach millions of additional users. Triller Corp. additionally owns Triller Sports, Bare-Knuckle Fighting Championship (BKFC); Amplify.ai, a leading machine-learning, AI platform; and TrillerTV, a premier global PPV, AVOD, and SVOD streaming service. For more information, visit www.triller.co.

Established in 1993, AGBA is a leading, multi-channel business platform that incorporates cutting-edge machine learning and offers a broad set of financial services and healthcare products to consumers through a tech-led ecosystem, enabling clients to unlock the choices that best suit their needs. Trusted by over 400,000 individual and corporate customers, the Group is organized into four market-leading businesses: Platform Business, Distribution Business, Healthcare Business, and Fintech Business. For more information, please visit www.agba.com.

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s goals and strategies; the Company’s future business development; product and service demand and acceptance; changes in technology; economic conditions; the outcome of any legal proceedings that may be instituted against us following the consummation of the business combination; expectations regarding our strategies and future financial performance, including its future business plans or objectives, prospective performance and opportunities and competitors, revenues, products, pricing, operating expenses, market trends, liquidity, cash flows and uses of cash, capital expenditures, and our ability to invest in growth initiatives and pursue acquisition opportunities; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in Hong Kong and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC, the length and severity of the recent coronavirus outbreak, including its impacts across our business and operations. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof.

Strap in: GoDaddy Reveals 2025 Super Bowl Spot

Actor Walton Goggins’ Most Challenging Role – Small Business Owner – Made Easy Through Power of AI

TEMPE, Ariz., Feb. 5, 2025 /PRNewswire/ — GoDaddy (NYSE: GDDY) debuted its Super Bowl commercial today, featuring GoDaddy Airo® and two-time EMMY® award-nominated actor Walton Goggins.

The ad, titled “Act Like You Know,” showcases how GoDaddy Airo® brings small business ideas like Walton Goggins Goggle Glasses to life through AI, giving entrepreneurs the tools to look and feel like they know what they’re doing.

“When we set out to tell the story of empowering entrepreneurs with GoDaddy Airo, we knew we wanted to tell that story through the lens of an actual entrepreneur,” said GoDaddy Chief Marketing Officer Fara Howard. “Walton was the perfect partner—he had a passion for entrepreneurship and eyewear, and GoDaddy Airo could help him bring it to life. This campaign is all about proving that with the right AI tools, anyone can build a business and confidently feel like they know what they’re doing. We’re proud to show the value of GoDaddy Airo to a massive audience on game day.”

GoDaddy Airo® Drives the Return to Big Game Advertising
In 180 countries and counting, GoDaddy Airo® is an AI-powered experience that enables entrepreneurs to establish and grow their online presence by generating domain names, logos, fully built websites and marketing, social media content and commerce capabilities. With more than 3 million customers tapping into the power of GoDaddy Airo® in the U.S. alone, its impact on small businesses inspired GoDaddy’s return to Super Bowl advertising after an eight-year hiatus.

Walton Goggins Goggle Glasses: An Example of the Power of GoDaddy Airo®
Goggins is known for his scene-stealing performances in “Fallout,” “The Righteous Gemstones,” “Vice Principals,” “The Hateful Eight,” “Justified” and the upcoming season of “The White Lotus.” As an actor, Goggins can make you believe he knows what he’s doing in just about any role—from a post-apocalyptic bounty hunter to a power-hungry vice principal—even when he doesn’t. But his toughest job yet isn’t one he plays onscreen; it’s his real-life role as a small business owner.

Walton launched Walton Goggins Goggle Glasses last year, offering retro-futuristic hybrid eyewear. GoDaddy Airo® helped his Goggle Glasses brand create a logo, website and social content, transforming an idea into a business like a seasoned pro. Small business owners like Goggins can focus on what they do best and let GoDaddy Airo®, using the power of AI, take care of the rest.

“As an entrepreneur, you need more than just an idea—you need the confidence and know-how to turn that idea into something,” said Walton Goggins. “For me, that’s where GoDaddy Airo came in. It filled in the gaps and made Walton Goggins Goggle Glasses a reality.”

The Spot: “Act Like You Know”
The ad opens with a close-up of Goggins. “Actors. We can make you believe we know what we’re doing, when in fact, we do not.” Various scenes depict Goggins playing roles he could not perform in real life, first as a detective absentmindedly traipsing through a sensitive crime scene. Then he’s an astronaut floating inside a space station, where he manipulates complex controls and admits, “I have no idea what these buttons do,” as he accidentally launches a fellow astronaut into deep space. Next, he’s a race car driver, dramatically shifting gears…in a car that he’s inadvertently driving backwards.

The spot shifts to Goggins entering his office, where boxes of Walton Goggins Goggle Glasses line the walls. There he acknowledges working as a small business owner is his hardest role yet. That’s because “I have no idea what I’m doing… but GoDaddy Airo® does, using AI to build a logo, website and social content.” Goggins confidently shows off his beautiful website created with GoDaddy Airo®. Wearing his signature namesake eyewear, Goggins declares: “If your goggles ain’t Goggins, they don’t belong on your noggins.”

Goggins then delivers the ad’s final line: “With GoDaddy Airo, it’s like you know what you’re doing.”

The spot also features a cameo appearance by Auguste Goldman, a GoDaddy veteran of nearly 18 years, as a police officer behind Goggins at the fake crime scene. Goldman has worn many hats throughout the years, including Chief Technology Officer, Chief People Officer and head of the company’s award-winning Care & Services team. Now he can add “Super Bowl extra” to the list.

What to Expect During the Big Game and Beyond
GoDaddy’s 30-second ad will air during the two-minute warning in the fourth quarter of the game on February 9. The spot is also now available on GoDaddy’s YouTube, X, Instagram and Facebook channels. GoDaddy also released an extended version available on YouTube.

The Super Bowl moment begins a yearlong, multi-channel marketing campaign in the U.S. across television, over-the-top (OTT) services, YouTube, out-of-home, social media and influencer marketing. The campaign, featuring Goggins, will continue highlighting GoDaddy Airo® as the ultimate small business partner.

About GoDaddy
GoDaddy helps millions of entrepreneurs globally start and scale their businesses. People come to GoDaddy to name their idea, build a website and logo, sell their products and services, and accept payments. GoDaddy Airo™, the company’s AI-powered experience, makes growing a small business faster and easier by helping them to get their idea online in minutes, drive traffic and boost sales. GoDaddy’s expert guides are available 24/7 to provide assistance. To learn more about the company, visit www.GoDaddy.com.

Source: GoDaddy Inc.

 

 

GoDaddy 30 second spot - Dressing Room Scene
GoDaddy 30 second spot – Dressing Room Scene

 

GoDaddy 30 second spot - Detective Scene
GoDaddy 30 second spot – Detective Scene

 

GoDaddy 30 second spot - Race Car Driver Scene
GoDaddy 30 second spot – Race Car Driver Scene

 

GoDaddy 30 second spot - End Scene
GoDaddy 30 second spot – End Scene

 

Video – https://www.youtube.com/watch?v=Mc-XvA9sNKU
Video – https://www.youtube.com/watch?v=CHbOUpiHiwc
Photo – https://laotiantimes.com/wp-content/uploads/2025/02/godaddy_superbowl_image13.jpg
Photo – https://laotiantimes.com/wp-content/uploads/2025/02/godaddy_superbowl_image09.jpg
Photo – https://laotiantimes.com/wp-content/uploads/2025/02/godaddy_superbowl_image10.jpg
Photo – https://laotiantimes.com/wp-content/uploads/2025/02/godaddy_superbowl_image08.jpg
Logo – https://laotiantimes.com/wp-content/uploads/2025/02/godaddy_logo.jpg

Cyient and Micware Navigations Forge Strategic Alliance to Shape the Future of Mobility

HYDERABAD, India, Feb. 5, 2025 /PRNewswire/ — Cyient, a global Intelligent Engineering services company, announced that it entered into a memorandum of understanding with Micware Navigations, a leader in navigation and mobility services. As per the MoU, both companies have agreed to work in partnership across mutual engineering services support, customer introduction, and marketing strategy.

This strategic partnership between Cyient and Micware Navigations aims to deliver transformative solutions for intelligent mobility, focusing on safer, smarter, and more sustainable transportation systems. By leveraging Cyient’s engineering excellence and Micware Navigations’ expertise in mobility software, the collaboration will develop integrated solutions that cater to the evolving needs of modern transportation ecosystems.

“Our partnership with Micware Navigations reinforces our commitment to engineering a better future through innovation and collaboration. By combining Cyient’s deep expertise in engineering and digital transformation with Micware Navigations’ pioneering advancements in navigation and mobility solutions, we aim to redefine the landscape of intelligent transportation. This partnership will enable us to create safer, smarter, and more sustainable mobility solutions that address the critical needs of an evolving Automotive & Mobility landscape, paving the way for next-generation ecosystems,” said, Joby Joseph, Vice President & Country Manager (Japan), Cyient.

“We are pleased to collaborate with Cyient and bring together our shared vision for advancing intelligent mobility. Our expertise in developing cutting-edge navigation and mobility solutions, combined with Cyient’s engineering capabilities. This partnership represents a step forward in addressing the challenges of modern transportation by leveraging technology and innovation to deliver impactful, scalable solutions that benefit industries and communities worldwide,” said, Kenta Imaida, President, Micware Navigations.

About Cyient

Cyient (Estd: 1991, NSE: CYIENT) delivers intelligent engineering solutions across products, plants, and networks for over 300 global customers, including 30% of the top 100 global innovators. As a company, Cyient is committed to designing a culturally inclusive, socially responsible, and environmentally sustainable tomorrow together with our stakeholders.

For more information, please visit www.cyient.com
Follow news about the company at @Cyient

About Micware Navigations.

Micware Navigations, established in May 2008, is a global leader in navigation, location-based services, and intelligent mobility solutions. With headquarters in Kobe, Japan and a strong presence across key markets, the company has built a stellar reputation for delivering innovative and reliable software platforms that power connected transportation ecosystems. Micware Navigations’ expertise lies in designing and developing advanced navigation systems, predictive analytics, and AI-driven mobility platforms tailored for the next generation of transportation solutions. The company’s offerings cater to a diverse range of industries, including automotive, logistics, smart cities, and autonomous vehicle development. Micware Navigations is a Key Member of the Micware Group, backed by leading Japanese carmakers such as Toyota and Honda.

For more information, please visit:
https://micware.co.jp/en/group/navigations/

Gowtham Uyalla

Kaizzen PR

+91 99892 22959

gowtham.uyalla@kaizzencomm.com

Phalguna Hari jandhyala

Cyient

Phalguna.Harijandhyala@cyient.com

Nanoprecise Sci Corp. Renews SOC 2 Type 2 Certification, Reinforcing Commitment to Security Excellence

EDMONTON, AB, Feb. 5, 2025 /PRNewswire/ — Nanoprecise Sci Corp., a global leader in Energy-Centered Predictive Maintenance, is pleased to announce the successful renewal of its SOC 2 Type 2 certification, further solidifying its ongoing commitment to maintaining the highest standards of security, confidentiality, and operational excellence.

Nanoprecise_SOC_2_Type_2
Nanoprecise_SOC_2_Type_2

The renewal of this certification, attested by Prescient Assurance LLC, confirms that Nanoprecise’s systems and controls continue to meet the AICPA’s Trust Service Criteria for Security. This comprehensive audit assesses the design and operational effectiveness of Nanoprecise’s controls and processes over an extended period, ensuring that the company’s solutions consistently protect sensitive customer data and uphold the integrity of its services.

We are proud to have successfully renewed our SOC 2 Type 2 certification, which further affirms our ongoing commitment to the security and privacy of our customers’ data,” said Faizan Ahmad Wani, Senior Manager – IT, Security & Compliance at Nanoprecise. “This renewal reflects our continued focus on safeguarding customer information while providing reliable, secure solutions to support their business needs.

The SOC 2 Type 2 certification ensures Nanoprecise’s commitment to safeguarding sensitive data. In predictive maintenance, where real-time monitoring and AI insights are critical, this certification reflects Nanoprecise’s rigorous security measures, including data encryption and access controls. It guarantees the integrity of solutions that help companies optimize operations, reduce energy consumption, and extend equipment lifecycles, all while maintaining the highest data security standards.

Renewing our SOC 2 Type 2 certification highlights our commitment to security and meeting the highest industry standards,” said Sunil Vedula, Founder and CEO of Nanoprecise Sci Corp. “It reflects the trust our customers place in us and reinforces our dedication to providing secure, reliable solutions that support their operational and sustainability goals.

About Nanoprecise Sci Corp.

Nanoprecise Sci Corp. provides end-to-end predictive maintenance solutions that leverage IoT and AI technology to monitor and optimize energy consumption, equipment health, and operational efficiency. Focused on Energy-Centered Maintenance (ECM), Nanoprecise helps organizations in various industries improve asset reliability, reduce CO2 emissions, and minimize unplanned downtime.

For more information about Nanoprecise Sci Corp. and its secure predictive maintenance solutions, visit nanoprecise.io.